{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-097764","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.080686+00:00","generated_at":"2026-06-03T22:21:31.931572+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify","bullets":["All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.","Control arm (transplant alone) had 2 relapses at ~6 months and 1 death; only 1 of 8 achieved complete donor chimerism.","Solid tumor: >40 patients screened; ~60% qualify for at least one TCR-T, ~30% eligible for multiplex (T-Plex) therapy.","First 3 solid tumor patients expected to be dosed early May 2024; initial data from singleplex and multiplex cohorts in H2 2024.","Heme: expansion cohorts at Phase 2 dose planned Q3 2024; Phase 1 enrollment completion and 1-year data in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-097764","json":"https://secwatch.observer/filing/0001193125-24-097764.json","markdown":"https://secwatch.observer/filing/0001193125-24-097764.md","text":"https://secwatch.observer/filing/0001193125-24-097764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/0001193125-24-097764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/d820546d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:21:31.931572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}